Evaxion A/S (EVAX)

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Ticker
EVAX
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$23.19M
52-week range
$2.42 - $6.92

Valuation

Share price
$2.54 (close of Nov 18, 2026)
P/E (TTM)
-2.78x
Price to book
1.36x
Price to free cash flow
-3.49x
Enterprise value
$7.46M
Book value per share
$2.04

Price performance

PeriodChange
1 day-8.63%
5 days-12.71%
1 month-10.25%
3 months-19.37%
6 months-37.90%
Year to date-46.75%
1 year-51.71%
3 years-93.04%
5 years-99.07%
All time-99.49%

Short interest

As of
Oct 30, 2026
Short % of float
0.36%
Shares short
27.57K
Days to cover
0.15
Change since prior report
-58.88%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-45.23%
Return on invested capital
-33.92%
Return on assets
-27.13%
Return on capital employed
-38.23%
Net margin
-102.38%
EBITDA margin
-122.66%
Revenue growth
125.12%

Cash flow and balance sheet

Free cash flow yield (TTM)
-28.62%
Current ratio
5.85x
Net debt to EBITDA
2.21x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$7.53M
EBITDA
-$9.23M
Net income
-$7.71M
Earnings per share
$-1.00
Research and development
$9.97M
Interest expense
$4.00M
Shares outstanding
6.41M

Income statement by year

Period endRevenueNet incomeEPS
2025-12-31$7.53M-$7.71M-$1.00
2024-12-31$3.34M-$10.57M-$10.00
2023-12-31$73.00K-$22.13M-$40.50
2022-12-31--$23.17M-$49.00
2021-12-31--$24.53M-$63.00
2020-12-31--$15.02M-$48.50
2019-12-31--$11.20M-$40.50
2018-12-31--$5.54M-$21.43

Margins and returns by year

Period endNet marginReturn on equityReturn on capital
2025-12-31-102.38%-45.23%-33.92%
2024-12-31-316.00%--165.04%
2023-12-31-30,308.22%--
2022-12-31--279.04%-131.98%
2021-12-31--75.63%-71.02%
2020-12-31--213.38%-212.68%
2019-12-31--119.58%-106.81%
2018-12-31---63.23%

Cash and debt by year

Period endCashDebt
2025-12-31$23.23M$5.35M
2024-12-31$5.95M$8.01M
2023-12-31$5.58M$8.49M
2022-12-31$13.18M$7.86M
2021-12-31$32.17M$1.04M
2020-12-31$5.83M-
2019-12-31$9.56M-
2018-12-31$7.43M-
2017-12-31$468.00K-

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$6.64M$307.00K
2024-12-31-$12.94M$357.00K
2023-12-31-$17.78M$479.00K
2022-12-31-$26.07M$942.00K
2021-12-31-$23.23M$1.38M
2020-12-31-$12.59M$3.41M
2019-12-31-$7.08M$2.36M
2018-12-31-$2.00M$2.07M

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-20Jun 2026-
2026-05-07Mar 2026-
2026-03-05Dec 2025-
2025-11-06Sep 2025-
2025-08-14Jun 2025-$0.50
2025-05-27Mar 2025-$0.65
2025-04-01Dec 2024-
2024-10-31Sep 2024-$0.12

Filings and sources

Company website
evaxion.ai
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades